Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.